These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

534 related items for PubMed ID: 30898339

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
    Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, Perrone RD, Ouyang J, Blais JD, Czerwiec FS, TEMPO 3:4 Trial Investigators.
    Clin J Am Soc Nephrol; 2016 May 06; 11(5):803-811. PubMed ID: 26912543
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang JJ, Czerwiec FS.
    Am J Kidney Dis; 2011 May 06; 57(5):692-9. PubMed ID: 21333426
    [Abstract] [Full Text] [Related]

  • 9. Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan.
    Muto S, Okada T, Shibasaki Y, Ibuki T, Horie S.
    Clin Exp Nephrol; 2021 Sep 06; 25(9):1003-1010. PubMed ID: 34089122
    [Abstract] [Full Text] [Related]

  • 10. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.
    Oguro M, Kogure Y, Hoshino J, Ubara Y, Mizuno H, Sekine A, Kawada M, Sumida K, Hiramatsu R, Hasegawa E, Yamanouchi M, Hayami N, Suwabe T, Sawa N, Takaichi K.
    J Nephrol; 2018 Dec 06; 31(6):961-966. PubMed ID: 30357715
    [Abstract] [Full Text] [Related]

  • 11. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.
    Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, Ouyang J, Czerwiec FS, Blais JD, TEMPO 4:4 Trial Investigators.
    Nephrol Dial Transplant; 2018 Mar 01; 33(3):477-489. PubMed ID: 28379536
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan.
    Kramers BJ, van Gastel MDA, Boertien WE, Meijer E, Gansevoort RT.
    Am J Kidney Dis; 2019 Mar 01; 73(3):354-362. PubMed ID: 30578153
    [Abstract] [Full Text] [Related]

  • 14. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
    Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O, REPRISE Trial Investigators.
    N Engl J Med; 2017 Nov 16; 377(20):1930-1942. PubMed ID: 29105594
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
    Bennett H, McEwan P, Hamilton K, O'Reilly K.
    BMC Nephrol; 2019 Apr 23; 20(1):136. PubMed ID: 31014270
    [Abstract] [Full Text] [Related]

  • 17. A Post Hoc Analysis of Statin Use in Tolvaptan Autosomal Dominant Polycystic Kidney Disease Pivotal Trials.
    Shoaf SE, Ouyang J, Sergeyeva O, Estilo A, Li H, Leung D.
    Clin J Am Soc Nephrol; 2020 May 07; 15(5):643-650. PubMed ID: 32241780
    [Abstract] [Full Text] [Related]

  • 18. The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial.
    Muto S, Kawano H, Higashihara E, Narita I, Ubara Y, Matsuzaki T, Ouyang J, Torres VE, Horie S.
    Clin Exp Nephrol; 2015 Oct 07; 19(5):867-77. PubMed ID: 25663351
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.